EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Gozde Kavgaci iD, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.70042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Gozde Kavgaci und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. Hauptthemen laut MEDLINE: Colorectal Neoplasms, GTP Phosphohydrolases, Membrane Proteins, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Inc., Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate KRAS and NRAS mutations over an eight‐year period to provide a comprehensive understanding of the genetic landscape of metastatic colorectal cancer (mCRC) in Turkish patients. Tumor tissue samples were collected from 10 754 patients with mCRC between January 2015 and June 2023 from multiple centers across Turkey, and all genetic analyses were performed at a single facility. DNA was analyzed for mutations in codons 12, 13, 59, 61, 117, and 146 of the KRAS and NRAS genes using nested PCR and multiplex minisequencing techniques. Among the conclusive results from 10 681 patients, 46.6% (4982) had KRAS mutations, and 53.4% (5699) were wild‐type. The most common KRAS mutations were G12D (30.3%), G12V (20.1%), G13D (18.4%), and G12C (7.0%). Results from the 5699 KRAS wild‐type patients revealed that 480 (8.5%) had NRAS mutations, while 91.5% were NRAS wild‐type. The most frequent NRAS mutations were Q61K (19.7%), G12D (19.1%), and G12V (12%). This study provides a large‐scale, real‐world dataset of KRAS and NRAS mutation profiles in Turkish mCRC patients, contributing significantly to the understanding of the genetic characteristics of mCRC in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsGTP PhosphohydrolasesMembrane ProteinsProto-Oncogene Proteins p21(ras)MutationHumansTurkeyFemaleMaleMiddle AgedAgedNeoplasm MetastasisAdultAged, 80 and over

Stichwörter der Autor:innen

KRASNRASmetastatic colorectal cancerminisequencingreal‐world data

Substanzen

GTP PhosphohydrolasesNRAS protein, humanMembrane ProteinsProto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
  • Heliks R&D and Biotechnology Inc., Istanbul, Turkey.
  • Genetiks Genetic Diagnostic Center, Istanbul, Turkey.

ORCID-Profile: Gozde Kavgaci

Förderung

  • Amgen Inc.
  • Amgen

Zitieren

APA

Kavgaci, G., Akiva, I., Ozon, Y. H., Berkil, H., Karadayi, H., Dizdar, O., & Yalcin, S. (2025). Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey. Molecular Oncology. https://doi.org/10.1002/1878-0261.70042

Vancouver

Kavgaci G, Akiva I, Ozon YH, Berkil H, Karadayi H, Dizdar O, et al. Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey. Molecular Oncology. 2025. doi:10.1002/1878-0261.70042

BibTeX
@article{Kavgaci2025,
  author = {Kavgaci, Gozde and Akiva, Izzet and Ozon, Yavuz Hakan and Berkil, Hakan and Karadayi, Huseyin and Dizdar, Omer and Yalcin, Suayib},
  title = {Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.70042}
}
Kostenlos starten →